SREBF1 and type 2 diabetes mellitus: Coupled with evidence that SREBF1 expression decreases type 2 diabetes risk by increasing serum adiponectin [54, 55] and the clear relevance of ADIPOQ to adiponectin production, there is now considerable support for their direct regulatory potential in metabolic risk (Fig. 6c, d).